Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EPS (Weighted Average and Diluted) (2022 - 2025)

Atara Biotherapeutics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.36 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 414.29% year-over-year to -$0.36; the TTM value through Dec 2025 reached $3.01, up 125.62%, while the annual FY2025 figure was $2.57, 122.52% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.36 in Q4 2025 per ATRA's latest filing, down from -$0.32 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.5 in Q1 2025 to a low of -$16.91 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$3.68, with a median of -$0.78 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 9494.44% in 2023, then skyrocketed 161.95% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.73 in 2022, then crashed by 1806.85% to -$13.92 in 2023, then soared by 99.5% to -$0.07 in 2024, then crashed by 414.29% to -$0.36 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's EPS (Weighted Average and Diluted) are -$0.36 (Q4 2025), -$0.32 (Q3 2025), and $0.19 (Q2 2025).